|Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer|
AA Azad, SV Volik, AW Wyatt, A Haegert, S Le Bihan, RH Bell, ...
Clinical cancer research 21 (10), 2315-2324, 2015
|High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development|
D Lin, AW Wyatt, H Xue, Y Wang, X Dong, A Haegert, R Wu, S Brahmbhatt, ...
Cancer research 74 (4), 1272-1283, 2014
|Mutations in BMP4 cause eye, brain, and digit developmental anomalies: overlap between the BMP4 and hedgehog signaling pathways|
P Bakrania, M Efthymiou, JC Klein, A Salt, DJ Bunyan, A Wyatt, ...
The American Journal of Human Genetics 82 (2), 304-319, 2008
|Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer|
AW Wyatt, AA Azad, SV Volik, M Annala, K Beja, B McConeghy, ...
JAMA oncology 2 (12), 1598-1606, 2016
|Genomic hallmarks and structural variation in metastatic prostate cancer|
DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, ...
Cell 174 (3), 758-769. e9, 2018
|From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer|
AV Lapuk, C Wu, AW Wyatt, A McPherson, BJ McConeghy, S Brahmbhatt, ...
The Journal of pathology 227 (3), 286-297, 2012
|Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer|
M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ...
Cancer discovery 8 (4), 444-457, 2018
|The placental gene PEG10 promotes progression of neuroendocrine prostate cancer|
S Akamatsu, AW Wyatt, D Lin, S Lysakowski, F Zhang, S Kim, C Tse, ...
Cell reports 12 (6), 922-936, 2015
|Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer|
AW Wyatt, M Annala, R Aggarwal, K Beja, F Feng, J Youngren, A Foye, ...
JNCI: Journal of the National Cancer Institute 109 (12), 2017
|The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer|
JL Bishop, D Thaper, S Vahid, A Davies, K Ketola, H Kuruma, R Jama, ...
Cancer discovery 7 (1), 54-71, 2017
|SOX2 anophthalmia syndrome: 12 new cases demonstrating broader phenotype and high frequency of large gene deletions|
P Bakrania, DO Robinson, DJ Bunyan, A Salt, A Martin, JA Crolla, A Wyatt, ...
British Journal of Ophthalmology 91 (11), 1471-1476, 2007
|Targeting the adaptive molecular landscape of castration‐resistant prostate cancer|
AW Wyatt, ME Gleave
EMBO molecular medicine 7 (7), 878-894, 2015
|Novel heterozygous OTX2 mutations and whole gene deletions in anophthalmia, microphthalmia and coloboma|
A Wyatt, P Bakrania, DJ Bunyan, RJ Osborne, JA Crolla, A Salt, C Ayuso, ...
Human mutation 29 (11), E278-E283, 2008
|Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients|
N Lallous, SV Volik, S Awrey, E Leblanc, R Tse, J Murillo, K Singh, ...
Genome biology 17 (1), 10, 2016
|Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors|
D Quigley, JJ Alumkal, AW Wyatt, V Kothari, A Foye, P Lloyd, R Aggarwal, ...
Cancer discovery 7 (9), 999-1005, 2017
|Treatment outcomes and tumor loss of heterozygosity in germline DNA repair–deficient prostate cancer|
M Annala, WJ Struss, EW Warner, K Beja, G Vandekerkhove, A Wong, ...
European urology 72 (1), 34-42, 2017
|nFuse: discovery of complex genomic rearrangements in cancer using high-throughput sequencing|
A McPherson, C Wu, AW Wyatt, S Shah, C Collins, SC Sahinalp
Genome research 22 (11), 2250-2261, 2012
|Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth|
Y Yamamoto, Y Loriot, E Beraldi, F Zhang, AW Wyatt, N Al Nakouzi, F Mo, ...
Clinical cancer research 21 (7), 1675-1687, 2015
|Seeing clearly: the dominant and recessive nature of FOXE3 in eye developmental anomalies|
SU Iseri, RJ Osborne, M Farrall, AW Wyatt, G Mirza, G Nürnberg, C Kluck, ...
Human mutation 30 (10), 1378-1386, 2009
|Treatment of mCRPC in the AR-axis-targeted therapy-resistant state|
K Chi, SJ Hotte, AM Joshua, S North, AW Wyatt, LL Collins, F Saad
Annals of Oncology 26 (10), 2044-2056, 2015